Therapy News and Research

RSS

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen.

25 Sep 2015

NNFF's Lifetime Health-Science Achievement Award 2015 goes to John Crew and Ron Najafi

The National Necrotizing Fasciitis Foundation today announced that it has awarded NNFF's Lifetime Health-Science Achievement Award 2015 to John Crew, MD and Ron Najafi, PhD for "Excellence in Innovative Healthcare". Their pioneering work has improved care for patients with life-threatening 'flesh-eating' disease and other types of wounds.

25 Sep 2015

Novel brain-computer interface technology allows paralyzed man to walk

Novel brain-computer interface technology created by University of California, Irvine researchers has allowed a paraplegic man to walk for a short distance.

25 Sep 2015

UCSF researchers develop molecular 'on switch' that allows control over the actions of T cells

UC San Francisco researchers have engineered a molecular "on switch" that allows tight control over the actions of T cells, immune system cells that have shown great potential as therapies for cancer. The innovation lays the groundwork for sharply reducing severe, sometimes deadly side effects that have been a significant hurdle to advancing T cell-based treatments.

25 Sep 2015

HIV cure research may shift from single-therapy development model to combination therapy trials

The next five years of HIV research should shift gears from the classic single-therapy development model to moving directly from in vitro studies to combination therapy trials, authors argue in a new paper published online today.

25 Sep 2015

Alimera Sciences announces results from ongoing study on ILUVIEN

Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.

24 Sep 2015

ElastiMed raises $1 million investment

ElastiMed, a portfolio company of Trendlines Medical, announced this week that it raised $1 million, which includes an investment from Pix Vine Capital, a Singapore-based investment house.

24 Sep 2015

JRC, CERN to explore potential of accelerator-driven method for producing targeted alpha therapy for cancer

A novel, accelerator-driven method could produce nuclides for targeted alpha therapy of cancer in practically unlimited amounts, overcoming current obstacles for its wider use due to a limited production of alpha-emitters. The JRC and the Conseil Européen pour la Recherche Nucléaire have embarked to explore the potential of the jointly proposed method.

24 Sep 2015

WSU biomedical students create therapeutic speech development toy for kids with auditory disabilities

Hearing loss is one of the most common birth defects, with more than 12,000 children in the United States affected each year. Three students in Wichita State University's biomedical engineering program recognized this issue and designed their senior project to create a therapeutic toy to provide early intervention therapy for children with auditory disabilities.

24 Sep 2015

Hyperbaric oxygen therapy improves outcomes of umbilical cord blood transplant patients

For the past 27 years, cord blood transplants have been a life-saving treatment option for thousands of people with leukemia, non-Hodgkins lymphoma, Hodgkins disease and myelodysplastic disorders. Cord blood helps replace cancerous blood cells and replenish a patient's own bone marrow and immune system. Even with its success, researchers are continually looking for ways to improve the transplant process and increase cure rates.

24 Sep 2015

City of Hope receives gift to open new Judy and Bernard Briskin Center for Multiple Myeloma Research

The Judy and Bernard Briskin Family Foundation has announced a gift to launch the new Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope, the third named center within City of Hope's new Hematologic Malignancies and Stem Cell Transplantation Institute. The generous gift will enable the institution to further its already considerable accomplishments in the field of myeloma treatment and research.

24 Sep 2015

Discovery opens door to more targeted, effective treatments for cancer

In a discovery that could lead to more targeted and effective treatments for certain lung and prostate cancers, researchers at the University of Virginia School of Medicine have identified two new cancer-causing gene mutations - mutations that may be particularly susceptible to cancer-fighting drugs already approved by the federal Food and Drug Administration. One of the gene mutations also may play a key role in early menopause.

24 Sep 2015

TUM, Stanford University scientists create new cancer therapy concept

Pancreatic cancer is one of the most aggressive forms of cancer and one of the most difficult to treat. Its high resistance to treatment is a major problem, particularly in the advanced stages.

24 Sep 2015

Study explores effectiveness of frontline treatments for couples with unexplained infertility

A breast cancer drug with promise for improving the chance that couples with unexplained infertility can have a baby without increasing their risk of multiple births apparently does not deliver, according to a comparative study.

24 Sep 2015

Use of exergaming can improve physical and mental fitness among children with ASD

A study conducted by The University of Texas Medical Branch at Galveston says games used for exercising can improve physical and mental fitness in children with autism spectrum disorders.

24 Sep 2015

Innovative new device improves breast cancer treatment

A surgeon with the Breast Health Center at Women & Infants Hospital of Rhode Island, a Care New England hospital, is among the first in New England to adopt an innovative new device that improves the treatment of breast cancer by more precisely targeting radiation treatment and providing for better follow-up exams.

23 Sep 2015

Practical tips to help parents spot children's foot problems

Just part of growing up vs. the sign of a problem—managing children's health and wellness is complicated for parents, who often struggle to know which signs and symptoms are temporary and those that point to more serious concerns. As parents transition back to the regular routines of fall with school and sports, the American College of Foot and Ankle Surgeons offers practical tips to help parents know what their children's feet are telling them.

23 Sep 2015

Researchers design new type of nanocarrier to improve effectiveness of allergy shots

Whether triggered by cats, bees, pollen or mites, allergies are on the rise. And the bad news doesn't stop there. The only current therapy that treats their causes is allergen-specific immunotherapy -- or allergy shots -- which can cause severe side effects. Now, researchers report in Biomacromolecules the development of a potentially better allergy shot that uses nanocarriers to address these unwanted issues.

23 Sep 2015

Researchers extend innovative research towards a cure for type I diabetes

Associate Professor Shane Grey, of Sydney's Garvan Institute of Medical Research, together with collaborators from the Westmead Millennium Institute for Medical Research and the Children's Hospital at Westmead, have been awarded $3.3 million to extend their innovative research towards a cure for type I diabetes.

23 Sep 2015

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.

23 Sep 2015

Therapy News and Research

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

NNFF's Lifetime Health-Science Achievement Award 2015 goes to John Crew and Ron Najafi

Novel brain-computer interface technology allows paralyzed man to walk

UCSF researchers develop molecular 'on switch' that allows control over the actions of T cells

HIV cure research may shift from single-therapy development model to combination therapy trials

Alimera Sciences announces results from ongoing study on ILUVIEN

ElastiMed raises $1 million investment

JRC, CERN to explore potential of accelerator-driven method for producing targeted alpha therapy for cancer

WSU biomedical students create therapeutic speech development toy for kids with auditory disabilities

Hyperbaric oxygen therapy improves outcomes of umbilical cord blood transplant patients

City of Hope receives gift to open new Judy and Bernard Briskin Center for Multiple Myeloma Research

Discovery opens door to more targeted, effective treatments for cancer

TUM, Stanford University scientists create new cancer therapy concept

Study explores effectiveness of frontline treatments for couples with unexplained infertility

Use of exergaming can improve physical and mental fitness among children with ASD

Innovative new device improves breast cancer treatment

Practical tips to help parents spot children's foot problems

Researchers design new type of nanocarrier to improve effectiveness of allergy shots

Researchers extend innovative research towards a cure for type I diabetes

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News